ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BBOT / financials
PRQR (44) UPB (29) RNAC (15) WHWK (24) ⌘ Pro Terminal →

BridgeBio Oncology Therapeutics Inc. (BBOT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.31 -11.83% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.26

BridgeBio Oncology Therapeutics Inc. (BBOT) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $185.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BBOT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BBOT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $2.31 (-11.83% 1D, market cap $185.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BBOT ranks #682 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BBOT compare to PRQR and UPB in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BBOT carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PRQR (ProQR Therapeutics N.V.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $186.3M) and UPB (Upstream Bio Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $183.5M). Among the 5-stock peer group, BBOT leads on earnings multiple (N/A) while BBOT leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BBOT?
▼

Per BBOT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001869105), BridgeBio Oncology Therapeutics Inc. generated $408.3M in revenue (+80.3% YoY), -$134.0M in net income, and -$114.5M in free cash flow against $448.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.26 (-2.32%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510033
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (6)Whales (3)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.3% Base Target
$16 Bull$2 Base$2 Bear
📬 FREE BBOT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BBOT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY BBOT SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 20 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
41
Grade D$2.95-7.8% Next Q
Q2 (-2Q)
38
Grade E$2.72-1.1% Next Q
Q3 (-1Q)
36
Grade E$2.69-14.1% Next Q
Current
33
Grade E$2.31-8.9% Hist 90D α
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BBOT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BBOT currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.73) and Max Pain ($2.43) forces dealer call-delta covering toward $15.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BBOT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BBOT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How BBOT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$408.3MGross Profit $212.3M (52%)Cost of Sales $196.0MOp Profit $0 (0%)OpEx (R&D/SG&A) $212.3MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $116.7K
FY24
Rev $226.4M
FY25
Rev $408.3M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$408.3M52%-35.7%-$134.0M-$114.5M-45%
FY 2024$226.4M52%-35.7%-$74.3M-$55.1M-45%
FY 2023$116.7K52%-35.7%-$41.7K-$39.6K-35%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BBOT)

  • ✓Walkthrough of BBOT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BBOT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -72.07%▼ SUPPORT BREAKDOWN
2026-11-04O $2.62H $2.62L $2.31C $2.31VOL 579.6K
RES: $10.22SUP: $8.44SMA50: $4.73SMA200: $8.04
$11.45$8.97$6.49$4.02$1.54RES $10.22SUP $8.44$2.312026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BBOT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BBOT Butterfly Map → + Track BBOT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +80.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BBOT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BBOT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BBOT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BBOT)

Health Care Rank #682 of 1015 ⚔️ PRQR vs BBOT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BBOT vs. PRQR, UPB, RNAC, WHWK)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, BridgeBio Oncology Therapeutics Inc. (BBOT) ranks #682 by composite RQD confidence (33/100, grade E) and #583 by equity capitalization ($185.2M). Within this direct 5-issuer industry benchmark cohort, BBOT leads on earnings valuation at N/A trailing P/E, while BBOT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PRQR currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with BBOT at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BBOT ACTIVE
BridgeBio Oncology Therapeutics Inc.
E 33/100 — — -35.0% -11.83% $185.2M Benchmark Subject
PRQR
ProQR Therapeutics N.V.
D 44/100 — — — -5.04% $186.3M /prqr-vs-bbot →
UPB
Upstream Bio Inc.
E 29/100 — — -35.0% -1.76% $183.5M /upb-vs-bbot →
RNAC
Cartesian Therapeutics Inc.
E 15/100 — — -35.0% -2.31% $191.8M /rnac-vs-bbot →
WHWK
Whitehawk Therapeutics Inc.
E 24/100 — 89.4% -35.0% -3.70% $177.9M /whwk-vs-bbot →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001869105 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BridgeBio Oncology Therapeutics Inc. (BBOT) reported GAAP revenue of $408.3M (+80.3% vs. FY2024 revenue of $226.4M , and +349651.8% cumulative change since FY2023) , GAAP net income of -$134.0M, operating cash flow of -$113.9M, and free cash flow of -$114.5M (-107.9% YoY). On the balance sheet, BBOT closed FY2025 with $448.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $408.3M -$134.0M -$113.9M -$114.5M $448.4M —
FY2024 (FY) 2024-12-31 $226.4M -$74.3M -$55.0M -$55.1M $164.3M —
FY2023 (FY) 2023-12-31 $116.7K -$41.7K — — — —

3. BBOT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BBOT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $2.31 (-11.83% 1D, market cap $185.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, BBOT ranks #682 in composite RQD confidence.

How does BBOT compare to PRQR and UPB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BBOT carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PRQR (ProQR Therapeutics N.V.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $186.3M) and UPB (Upstream Bio Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $183.5M). Among the 5-stock peer group, BBOT leads on earnings multiple (N/A) while BBOT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BBOT?

Per BBOT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001869105), BridgeBio Oncology Therapeutics Inc. generated $408.3M in revenue (+80.3% YoY), -$134.0M in net income, and -$114.5M in free cash flow against $448.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BBOT trading relative to its 50-day, 200-day, and 52-week technical levels?

BBOT last traded at $2.31 (-11.83% on volume of 579,589 shares), positioning the stock -51.16% below its 50-day simple moving average ($4.73) and -71.27% below its 200-day simple moving average ($8.04). Across its 52-week range of $2.31 to $14.87, BBOT sits at the 0.0% percentile with a 14-day RSI of 20.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.02 to $2.60).

Direct Sub-Reports: BBOT RQD Cockpit BBOT 12M Forecast BBOT Earnings & Move BBOT Dividends & DRIP BBOT Insiders & 13F BBOT Whale Options BBOT Profit Sankey BBOT News & Why
ROARABLE RATING BRIEF • RQD 33/100 (E) ✓ SEC XBRL & RQD VERIFIED

BBOT — BridgeBio Oncology Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

BridgeBio Oncology Therapeutics Inc. (BBOT) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.31 (-11.83% 1D, market capitalization $185.2M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

BridgeBio Oncology Therapeutics Inc. (BBOT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..2B. Reported revenue is — for each period shown in the SEC financials.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), BridgeBio Oncology Therapeutics Inc. (BBOT) reported $408.3M in annual revenue (up from $226.4M in FY2024, +80.3% YoY) and -$134.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($116.7K revenue, -$41.7K net income) through FY2025, BBOT scaled operating cash flow to -$113.9M and free cash flow to -$114.5M, backed by $448.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.31 – $14.87 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the source data. The sector is listed as Health Care and the industry as Biotechnology: Pharmaceutical Preparations. Beyond these classifications, the sources provide no specific dependency mapping. A prospective investor should treat any ripple analysis for this company as unavailable in source data.

  • Key Question #1: Can BBOT sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $408.3M and free cash flow of -$114.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BBOT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BBOT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BridgeBio Oncology Therapeutics Inc. (BBOT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BBOT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BBOT Bull vs. Bear Conversation Board — What's Your Call at $2.31?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BBOT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BBOT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $3.25 (+24.0%)
📌 Pinned Debate

Cash rose to $373.7M in FY 2025 and analysts maintain Outperform and Buy ratings with a Moderate Buy consensus.

Here is why I am bullish on BBOT here at $2.62: Cash rose to $373.7M in FY 2025 and analysts maintain Outperform and Buy ratings with a Moderate Buy consensus.. Compare BBOT's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $2.49 are getting bought.

ArenaChamp_24 🐂 BULL

@TapeReader_Pro Agree on the RQD 33/100 quality, though with 1.0 beta I'm scaling in with half-size at $2.62 and keeping dry powder in case we test $2.44.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $2.17 (-17.2%)
Spot @ $2.62

ROIC of -35%, FCF yield of 0%, and FY 2025 free cash flow of -$114.5M leave the company without a demonstrated cash engine.

Careful chasing BBOT at $2.62. ROIC of -35%, FCF yield of 0%, and FY 2025 free cash flow of -$114.5M leave the company without a demonstrated cash engine.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $2.17 on multiple compression.

LIVE TAPE